Libra Infusions (DHA:LIBRAINFU) ROCE %: 0.00% (As of . 20)


DHA:LIBRAINFU Libra Infusions Ltd DHA:LIBRAINFU
20 GF Score
Price BDT642.40
View Full Analysis

What is Libra Infusions ROCE %?

Libra Infusions DHA:LIBRAINFU +0.45% 20 ROCE % is 0.00% as of . 20. GuruFocus rates DHA:LIBRAINFU with a GF Score™ of 20/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Libra Infusions's annualized ROCE % for the quarter that ended in . 20 was 0.00%.

Libra Infusions  (DHA:LIBRAINFU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Libra Infusions ROCE % Related Terms

Libra Infusions ROCE % Historical Data

* Premium members only.

The historical data trend for Libra Infusions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Libra Infusions ROCE % Chart

Libra Infusions Annual Data
Trend
ROCE %

Libra Infusions Semi-Annual Data
ROCE %
DHA:LIBRAINFU
20GF Score
Libra Infusions Ltd DHA:LIBRAINFU
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Libra Infusions ROCE % Calculation

Libra Infusions's annualized ROCE % for the fiscal year that ended in . 20 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Libra Infusions's ROCE % of for the quarter that ended in . 20 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is one times the annual (. 20) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Libra Infusions (DHA:LIBRAINFU) has a ROCE % of 0.00% as of . 20.
Is Libra Infusions' ROCE % too high?
Libra Infusions' current ROCE % is 0.00%. Overall, Libra Infusions has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Libra Infusions' ROCE % compare to SECI and LENSF?
Libra Infusions' ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Libra Infusions's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Libra Infusions stock overvalued right now?
Libra Infusions (DHA:LIBRAINFU) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Libra Infusions' overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Libra Infusions (DHA:LIBRAINFU), the current ROCE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Libra Infusions Business Description

Address I/7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka, BGD, 1216
Libra Infusions Ltd is engaged in manufacturing intravenous fluids. It provides products which are used for medical purposes involving surgical operations, loss of blood, weakness, and general hospitalization.
20GF Score

Get the complete analysis for DHA:LIBRAINFU

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT642.40
Price